Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

According to this contract, OliX must complete Phase 1 clinical trials for OLX75016. Following that, clinical development and commercialization will be handled by Eli Lilly and Company (NYSE ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

The company entered into a global licensing deal with South Korea’s OliX Pharmaceuticals that could be valued at up to $630 million. As per the agreement, Eli Lilly and Company (NYSE:LLY ...

Eli Lilly (LLY) has agreed to acquire Organovo Holdings ... This is Lilly’s second MASH deal this year, following its partnership with OliX Pharmaceuticals on the RNAi drug OLX75016.